Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation

Hsieh, Kang Lin; Wang, Yinyin; Chen, Luyao; Zhao, Zhongming; Savitz, Sean I; Jiang, Xiaoqian; Tang, Jing; Kim, Yejin

doi:10.21203/rs.3.rs-114758/v1

Cited by 33 publications

(25 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 231 articles (PubMed and Google Scholar), 91 were retained [ 3 , 12 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ,…”

Section: Update (16 June 2021) On Studies With Fiasmas In the Sars-cov-2 Infectionmentioning

confidence: 99%

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Loas

Corre

2021

Pharmaceuticals

View full text Add to dashboard Cite

The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy.

show abstract

Section: Update (16 June 2021) On Studies With Fiasmas In the Sars-cov-2 Infectionmentioning

confidence: 99%

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Loas

Corre

2021

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…The results showed that 380 KDTs have a direct relation with circuits of the COVID-19. In [ 174 ], the authors used a deep graph neural network to extract the candidate drug representation according to biological interactions. They demonstrated that the interactions between DNN and extensive interaction could facilitate the identification of candidate drugs.…”

Section: The Study Taxonomymentioning

confidence: 99%

Comprehensive Survey of Using Machine Learning in the COVID-19 Pandemic

et al. 2021

View full text Add to dashboard Cite

Since December 2019, the global health population has faced the rapid spreading of coronavirus disease (COVID-19). With the incremental acceleration of the number of infected cases, the World Health Organization (WHO) has reported COVID-19 as an epidemic that puts a heavy burden on healthcare sectors in almost every country. The potential of artificial intelligence (AI) in this context is difficult to ignore. AI companies have been racing to develop innovative tools that contribute to arm the world against this pandemic and minimize the disruption that it may cause. The main objective of this study is to survey the decisive role of AI as a technology used to fight against the COVID-19 pandemic. Five significant applications of AI for COVID-19 were found, including (1) COVID-19 diagnosis using various data types (e.g., images, sound, and text); (2) estimation of the possible future spread of the disease based on the current confirmed cases; (3) association between COVID-19 infection and patient characteristics; (4) vaccine development and drug interaction; and (5) development of supporting applications. This study also introduces a comparison between current COVID-19 datasets. Based on the limitations of the current literature, this review highlights the open research challenges that could inspire the future application of AI in COVID-19.

show abstract

“…In the first set of studies, (11,12,(14)(15)(16)(17)(18) the antiviral activity of FIASMAs against the SARS-CoV and MERS-CoV viruses was explored. In the second set of studies, different drugs were tested against the SARS-CoV-2 using in silico (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) and in vitro studies. (30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40) These are listed in Table 1.…”

Section: Fiasma's and Coronavirusesmentioning

confidence: 99%

Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS‐CoV‐2 infection?

Corre

Loas

2021

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective Infection by SARS‐CoV‐2, the virus responsible of COVID‐19, is associated with limited treatment options. The purpose of this study was to evaluate the rationale for repurposing functional inhibitors of acid sphingomyelinase (FIASMAs), several of which are approved medicines, for the treatment of SAR‐CoV‐2 infections. Comment We propose and discuss the FIASMAs’ lysosomotropism as a possible explanation for their observed in vitro activities against viruses, and more specifically against infections caused by coronaviruses such as SARS‐CoV‐2. Successful in vitro‐to‐in vivo translation of FIASMAs requires that their pharmacokinetics (dosing regimen and drug‐drug interactions) are matched with viral kinetics. What is new and conclusion Drug repurposing to ensure rapid patient access to effective treatment has garnered much attention in this era of the COVID‐19 pandemic. The observed lysosomotropic activity of small‐molecule FIASMA compounds suggests that their repurposing as potential drugs against SARS‐CoV‐2 is promising.

show abstract

Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation

Cited by 33 publications

References 79 publications

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

Comprehensive Survey of Using Machine Learning in the COVID-19 Pandemic

Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS‐CoV‐2 infection?

Contact Info

Product

Resources

About